Summary
The pilot program—Discovering New Therapeutic Uses for Existing Molecules —is the first major endeavor of the National Center for Advancing Translational Sciences (NCATS), which was established this year with a budget of $575 million. The collaborative program initially involves three pharmaceutical partners—Pfizer, AstraZeneca, and Eli Lilly & Co.—which have agreed to make 24 compounds available.
Description
“To accelerate our nation’s therapeutic development process, it is essential that we forge strong, innovative, and strategic partnerships across government, academia, and industry,” Department of Health & Human Services Secretary Kathleen Sebelius said at the May 3 rollout of the program. She added that this pilot is effectively the “crowdsourcing” of pharma compounds to the brightest drug development minds in the country.